


Ordering Information
Web www.encorbio.com
Email admin@encorbio.com
Phone 352-372-7022
Fax 352-372-7066

HGNC Name: VIM
UniProt: P08670
RRID: AB_2737582
Immunogen: Recombinant human vimentin expressed in and purified from *E. coli*
Format: Affinity purified antibody at 1mg/mL in 50% PBS, 50% glycerol plus 5mM NaN₃
Storage: Store at 4°C for short term, for longer term at -20°C
Recommended dilutions:
WB: 1:5,000. IF/ICC: 1:500-1,000. IHC: not recommended


References:

1. Franke WW, et al. Different intermediate-sized filaments distinguished by immunofluorescence microscopy. *PNAS* 75:5034-8 (1978).
2. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. *J. Cell Biol.* 143:1883-98 (1998).
3. Dahl D, et al. Vimentin, the 57 000 molecular weight protein of fibroblast filaments, is the major cytoskeletal component in immature glia. *Eur. J. Cell Biol.* 24:191-6 (1981).
4. Shaw, G. et al. An immunofluorescence microscopical study of the neurofilament triplet proteins, vimentin and glial fibrillary acidic protein within the adult rat brain. *Eur. J. Cell Biol.* 26:68-72 (1981).
5. Muller M, et al. Dominant cataract formation in association with a vimentin assembly disrupting mutation. *Hum. Molec. Genet.* 18:1052-7 (2009).
6. Zhai Y, et al. Targeted exome sequencing of congenital cataracts related genes: broadening the mutation spectrum and genotype-phenotype correlations in 27 Chinese Han families. *Sci. Rep.* 7:1219 (2017).
7. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. *Cell Mol. Life Sci.* 68:3033-46 (2011).
8. Wong KF, Luk JM. Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma. *Meth. Mol. Biol.* 2909:295-310 (2012).
9. Jia X, et al. Vimentin-a potential biomarker for therapeutic efficiency of HAART. *Acta Biochim. Biophys. Sin. (Shanghai)* 6:1001-6 (2014).

| Applications | Host | Isotype | Molecular Wt. | Species Cross-Reactivity |
|-----------------|------|---------|---------------|----------------------------|
| WB, ICC/IF, IHC | Goat | | ~50kDa | Hu, Mo, Rt, Ms, Co, Pi, Ho |



Western blot analysis of different cell lysates using goat pAb to vimentin, GPCA-Vim, dilution 1:5,000 in green. [1] protein standard, [2] HeLa, [3] HEK293, [4] NIH-3T3 and [5] C6 cell lysates. The GPCA-Vim antibody binds to the vimentin protein showing a single band at ~50kDa.



Immunofluorescent analysis of HeLa cell culture stained with goat pAb to vimentin, GPCA-Vim, dilution 1:500 in green, and costained with mouse mAb to actin, MCA-5J11, dilution 1:500 in red. Blue is Hoechst staining of nuclear DNA. GPCA-Vim antibody produces strong staining of intermediate filament network of the cytoskeleton, while actin antibody stains the submembranous actin-rich cytoskeleton, stress fibers and bundles of actin associated with cell adhesion sites.

Background:

Vimentin is a protein subunit of the intermediate or 10nm filaments found in the cytoplasm of many cell types (1). Intermediate filaments are relatively stable fibrous components of cells which appear to have primarily a mechanical function. Many cell lines such as HEK293, HeLa, 3T3 and Cos cells contain prominent vimentin networks (1). Vimentin containing filaments accumulate around aggresomes, cytoplasmic clumps of misfolded and often ubiquitinated proteins, and so vimentin antibodies provide one means to identify these structures (2). Vimentin is a major protein of eye lens and cornea, and found in mesenchymal tissues in adult mammals. In the CNS it is found in endothelia and developing neurons, developing and some mature astrocytes, microglia, mature Bergmann glia in the cerebellum, Müller glia in the retina and ependymal cells (e.g. 3,4). Mutations in the vimentin gene may cause cataracts (5,6), and elevated levels of vimentin in blood samples are associated with onset of cancer (7,8). Vimentin levels increase in a variety of cell types as they become cancerous, suggesting that increase in expression of this protein is a useful diagnostic marker of the epithelial-mesenchymal transition, an important step in the metastasis of carcinoma cells (9).

The GPCA-Vim antibody can be used to study stem cells and generally to reveal the intermediate filament cytoskeleton. The immunogen used to generate this antibody was full length recombinant human vimentin, PROT-r-Vim, expressed in and purified from *E. coli*. Vimentin is a major protein of eye lens and cornea, and this mutation renders the molecule unable assemble into normal 10nm filaments. Antibodies to vimentin are useful in studies of stem cells and generally to reveal the filamentous cytoskeleton. The antibody works well on all mammals tested to date for western blotting, IF and ICC, but is not recommended for IHC. It was generated in goat by standard procedures. The same vimentin immunogen was used to produce two high quality epitope mapped monoclonal antibodies to vimentin MCA-2A52 and MCA-2D1, and also widely used rabbit and chicken polyclonal antibodies RPCA-VIM and CPCA-VIM.

FOR RESEARCH USE ONLY. NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE.

Abbreviation Key:

mAb—Monoclonal Antibody **pAb**—Polyclonal Antibody **WB**—Western Blot **IF**—Immunofluorescence **ICC**—Immunocytochemistry
IHC—Immunohistochemistry **E**—ELISA **Hu**—Human **Mo**—Monkey **Do**—Dog **Rt**—Rat **Ms**—Mouse **Co**—Cow **Pi**—Pig **Ho**—Horse **Ch**—Chicken
Dr—*D. rerio* **Dm**—*D. melanogaster* **Sm**—*S. mutans* **Ce**—*C. elegans* **Sc**—*S. cerevisiae* **Sa**—*S. aureus* **Ec**—*E. coli*.